Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes
Search for MSDS (Material Safety Data Sheet) by Product Number
Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides
Sigma-Aldrich is a leading Life Science and High Technology Materials company focused on enabling science to improve the quality of life
This means that there could be products that you require, that we are presently unable to import e.g. animal serums, albumins, gelatins, milk powders. Please contact the office if you are unsure on whether your product can be supplied.Read More
Delivers Accurate and Reliable Results for Molecular Diagnostic Assays
Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, released ONYX QUENCHER™, a proprietary quencher for quantitative real-time PCR (qPCR) that improves assay signal quality. ONYX QUENCHER enhances Sigma Life Science’s portfolio of qPCR probes, reagents and oligonucleotide services. To learn more about ONYX QUENCHER, visit sigma.com/darkquencher.
Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (www.sigma-aldrich.com/safc), its custom manufacturing services business unit, has entered into a services agreement with CatScI Ltd. (www.catsci.com), a UK-based catalysis company focused on maximizing yield, optimizing quality, reducing waste and minimizing chemical development costs through reaction understanding. SAFC customers will immediately benefit from the relationship through rapid access to new reactions, homogeneous and heterogeneous catalysis, biocatalysts, solvent selection and process development, in addition to metal removal, recovery and recycling services.
Sigma-Aldrich Corporation’s (NASDAQ: SIAL) custom manufacturing services business unit, SAFC® Commercial (www.sigma-aldrich.com/safc), has broadened production at its Arklow, Ireland, facility to include new PharmaGrade products. Production of the raw materials began at the site earlier this year and complements the existing offering of highly regulated active and non-active pharmaceutical ingredients manufactured at the site. All products manufactured at the Arklow facility meet and exceed U.S. Food and Drug Administration (FDA) regulations; follow Current Good Manufacturing Practices (cGMPs) for biopharmaceutical production; and comply with International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) requirements.